Literature DB >> 28668867

Radiosurgery with a Rotating Gamma System: A Very Effective Treatment for Symptomatic Cerebral Cavernomas.

Pham Cam Phuong1, Nguyen Duc Luan2, Vo Thi Huyen Trang2, Steven E Schild3, Dirk Rades4,5, Mai Trong Khoa2,5.   

Abstract

AIM: To evaluate the value of radiosurgery with a rotating gamma-system (RGS) for cerebral cavernomas. PATIENTS AND METHODS: Seventy-nine patients with symptomatic cerebral cavernomas underwent RGS radiosurgery at the Bach Mai Hospital, Hanoi, Vietnam. Median dose (single fraction) was 20 Gy (range=14-26 Gy). Endpoints included effect on headache, seizures and tumor size.
RESULTS: Of 60 patients with headache, 17% had complete response, 82% partial response and 2% stable disease (best response). Of 39 patients with seizures, 31% had complete response, 64% partial response and 5% stable disease. Four patients developed recurrent seizures after 1 year. Regarding the size of cavernoma at 15 months, complete response was observed in 6%, partial response in 75%, stable disease in 15%, progression in 1% and pseudo-progression in 3% of patients. Bleeding within 2 years after RGS radiosurgery occurred in only five patients (6%). RGS dose had no significant impact on outcomes.
CONCLUSION: RGS radiosurgery provided very high rates of symptom relief in patients with cerebral cavernomas. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Cerebral cavernoma; Rotating-Gamma System; cavernous angioma; cavernous hemangioma; headache; radiosurgery; seizures; symptom relief

Mesh:

Year:  2017        PMID: 28668867     DOI: 10.21873/anticanres.11746

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Intralesional injection of triamcinolone acetonide for cavernous hemangiomas: A case report.

Authors:  Wen-Yan Wang; Luan-Hong Wang; Guang Huang; Zhen-Ying Lin; Han Lin
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.